Graminex, which is rye flower pollen extract, has been used in Europe for more than 35 years to manage prostatitis and BPH (enlarged prostate). It has been shown to be quite effective in several double-blind clinical studies in the management of enlarged prostate. The overall success rate of Graminex health benefits in patients with BPH is about 70 percent. Patients who respond typically have reductions of nighttime and daytime urinary frequency of around 70 percent, as well as significant reductions in residual urine volume increasing bladder emptying. Graminex has been shown to possess some anti-inflammatory activity and it causes the bladder to contract while simultaneously relaxing the urethra.

A double-blind, placebo-controlled study published in the British Journal of Urology included 53 men with outflow obstruction due to BPH, who took Graminex for six months. The result: 69 percent of the men who took Graminex said their symptoms had improved. The improvements included a significant decrease in residual urine and in the diameter of the prostate based on ultrasound. The authors concluded that “Graminex has a beneficial effect in BPH and may have a place in the treatment of patients with mild or moderate symptoms of outflow obstruction.”

A Japanese study evaluated the use of Graminex in 79 patients with BPH who ranged in age from 62 to 89 years. Graminex was administered three times daily, 2 tablets of 63 mg (378 mg) each per dose, for more than 12 weeks. At the end of the study, urine maximum flow rate and average flow rate had increased significantly, while residual urine volume had decreased significantly, and 28 of the men who took Graminex for longer than 1 year showed a mean decrease of prostatic volume. Improvements in specific factors were as follows: urgency or discomfort 76.9% improvement; dysuria, 71.4%; nocturia, 56.8%; incomplete emptying, 66.2%; prolonged voiding, 64.1%; delayed voiding, 62.2%; intermittency, 60.6%; and post void dribbling, 42.7%.

The Cochrane Database Systemic Review reported on four studies that involved a total of 444 men who had BPH. The trials lasted from 12 to 24 weeks, and three of the studies used a double-blind approach. All of the studies used Graminex. Overall, Graminex improved urinary symptoms when compared with the placebos. Specifically, Graminex reduced the need to get up several times during the night (nocturia) to urinate.

Sign up for our Video Newsletter & Informative Reports